Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.32 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28248321 | 0.97 | GABRR1 (0.32) | GABRR1GABBR2GABBR1 | |
| Bromide SCHEMBL28248884 | 0.97 | GABRR1 (0.32) | GABRR1GABBR2GABBR1 | |
| Hydrochloric Acid SCHEMBL28248327 | 0.97 | GABRR1 (0.32) | GABRR1GABBR2GABBR1 | |
| Iodide SCHEMBL28865549 | 0.97 | GABRR1 (0.32) | GABRR1GABBR2GABBR1 | |
| SCHEMBL1291871 | 0.84 | DNM1 (0.32) | — | |
| SCHEMBL2565949 | 0.82 | FDPS (0.33) | — | |
| SCHEMBL10355799 | 0.79 | FDPS (0.33) | GABRR1GABBR2GABBR1 | |
| SCHEMBL15134141 | 0.78 | GABRR1 (0.33) | GABRR1GABBR2GABBR1 | |
| SCHEMBL20186677 | 0.77 | — | — | |
| SCHEMBL10285142 | 0.77 | TSHR (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108722479-B | Ionic liquid catalyst, preparation method and application thereof | 华中科技大学 | 2020-05-19 | — | — | CN | disclosed |
| EP-3294741-B1 | 5-SUBSTITUTED 7-[4-(2-PYRIDYL)PHENYLMETHYLAMINO]-3-ISO PROPYLPYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES, USE THEREOF AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS | USTAV EXPERIMENTALNI BOTANIKY AV CR V V I (CZ) | 2019-05-01 | — | — | EP | disclosed |
| US-9957273-B2 | 5-substituted 7- [4-(2-pyridyl)phenylmethylamino] -3-isopropylpyrazolo4,3-D]pyrimidine derivatives, use thereof as medicaments, and pharmaceutical compositions | USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I. (CZ) | 2018-05-01 | — | — | US | disclosed |
| US-20180072736-A1 | 5-SUBSTITUTED 7-[4-(2-PYRIDYL)PHENYLMETHYLAMINO]-3-ISOPROPYLPYRAZOLO4,3-D]PYRIMIDINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I. (CZ) | 2018-03-15 | — | — | US | disclosed |
| EP-1433801-B1 | Isocyanate crosslinked episulfide resin composition | MITSUBISHI GAS CHEMICAL CO (JP) | 2006-04-19 | — | — | EP | disclosed |
| WO-2001040193-A1 | METHOD FOR THE SYNTHESIS OF PYRAZOLINES | CHEMRX ADVANCED TECHNOLOGIES, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| EP-1075261-A1 | MYCOBACTERIAL INHIBITORS | AstraZeneca AB (SE) | 2001-02-14 | — | — | EP | disclosed |
| WO-1999065483-A1 | MYCOBACTERIAL INHIBITORS | ASTRAZENECA AB (SE) | 1999-12-23 | — | — | WO | disclosed |
| US-4585869-A | ANTIINFLAMMATORY, ANALGESIC, ANTIULCER | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1986-04-29 | — | — | US | disclosed |
| US-4549023-A | ANTINFLAMMATORY AGENTS, ANALGESICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1985-10-22 | — | — | US | disclosed |
| EP-0049779-B1 | 3-AMINOINDAZOLE DERIVATIVES AND PROCESS FOR PREPARATION THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1984-10-31 | — | — | EP | disclosed |
| US-4474964-A | 3-Aminoindazole derivatives | ASAHI, KASEI, KOGYO, KABUSHIKI, KAISHA (JP) | 1984-10-02 | — | — | US | disclosed |
| EP-0049779-A1 | 3-Aminoindazole derivatives and process for preparation thereof | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1982-04-21 | — | — | EP | disclosed |
| US-4048322-A | Bronchially effective xanthene-9-carboxylates | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1977-09-13 | — | — | US | disclosed |
| US-4044146-A | CHOLINOLYTIC, BRONCHOSPASMOLYTIC | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072736-A1 | 5-SUBSTITUTED 7-[4-(2-PYRIDYL)PHENYLMETHYLAMINO]-3-ISOPROPYLPYRAZOLO4,3-D]PYRIMIDINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | CDK5, CDK2, CDK4 | GABRR1 4790/4885GABBR2 4540/4885GABBR1 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.